Ionis Pharmaceuticals (IONS) Equity Average (2010 - 2026)

Ionis Pharmaceuticals has reported Equity Average for 17 years, with the latest figure at $490.3 million in Q1 2026.

• For the quarter ending Q1 2026, Equity Average fell 7.85% year-over-year to $490.3 million; the trailing twelve-month figure through Mar 2026 stood at $490.3 million (down 7.85% YoY), and the FY2025 full-year result was $538.7 million, up 10.5% from the prior year.
• Equity Average for Q1 2026 stood at $490.3 million, down from $553.5 million in the prior quarter.
• The five-year high for Equity Average was $740.7 million in Q1 2022, with the low at $280.1 million in Q2 2024.
• Average Equity Average over 5 years is $516.2 million, with a median of $532.0 million recorded in 2025.
• Year-over-year, Equity Average sank 39.85% in 2023 and jumped 97.68% in 2025.
• Tracing IONS's Equity Average over 5 years: stood at $583.6 million in 2022, then sank by 39.85% to $351.1 million in 2023, then jumped by 78.14% to $625.4 million in 2024, then slipped by 11.49% to $553.5 million in 2025, then decreased by 11.43% to $490.3 million in 2026.
• The last three Equity Average figures came in at $490.3 million (Q1 2026), $553.5 million (Q4 2025), and $624.8 million (Q3 2025), per Business Quant data.

Peer Comparison